The Role of Aspirin in Preventing Gastrointestinal Cancers
Author Information
Author(s): Maryam Ibrahim, Janusz Jankowski
Primary Institution: University Hospitals Leicester
Hypothesis
Can aspirin reduce the occurrence of gastrointestinal cancers?
Conclusion
Aspirin use is associated with a significant reduction in the risk of various gastrointestinal cancers.
Supporting Evidence
- Aspirin use is associated with a 36% reduction in colorectal cancer incidence.
- Low-dose aspirin therapy is linked to a 41% and 54% risk reduction for esophageal and gastric cancer, respectively.
- Regular aspirin use has shown protective changes in gut microbiota.
Takeaway
Taking aspirin can help prevent certain types of stomach and bowel cancers, especially if you start taking it when you're middle-aged.
Methodology
The study reviewed data from randomized control trials, meta-analyses, cohort studies, and population-based studies on aspirin's effects on GI cancers.
Potential Biases
Potential biases include recall bias and selection bias from case-control studies.
Limitations
The main limitation is the risk of bleeding associated with aspirin use, which can complicate its use as a preventive measure.
Participant Demographics
The study included over 300,000 participants from various demographics.
Statistical Information
P-Value
<0.001
Confidence Interval
95% CI 0.69 – 0.78
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website